Arsenal™ Osteotomy Instrument Set Launched to Support Complex Spinal Cases
Featured at NASS Booth #1147
CARLSBAD, Calif., Sept. 17, 2015 (GLOBE NEWSWIRE) -- Alphatec Holdings, Inc. (Nasdaq:ATEC), the parent company of Alphatec Spine, Inc., a global provider of spinal fusion technologies, announced today that the Company has launched its Arsenal Osteotomy Instrument Set, further expanding the Arsenal Spinal Fixation System launched earlier this year. The Arsenal Osteotomy Instrument Set is a foundational component supporting Alphatec’s Arsenal Deformity pipeline program that is targeted for beta launch in the first quarter of 2016. The Company is showcasing Arsenal and the Arsenal Osteotomy Instrument Set, as well its portfolio of products at the upcoming North American Spine Society (NASS) Annual Meeting being held at McCormick Place West, Chicago, Illinois, from October 14th - 16th, 2015. Alphatec Spine will be located in booth number 1147.
Robert Eastlack, M.D., a board-certified orthopedic surgeon specializing in complex spinal conditions including spinal deformity, spinal reconstructions and revisions at Scripps Green Hospital, La Jolla, California, shares, “The Arsenal Osteotomy Instrument Set represents a great statement regarding Alphatec’s commitment to its deformity surgeons.” Dr. Eastlack successfully performed surgery on the first patient using the new Arsenal Osteotomy Instrument Set with the Arsenal Spinal Fixation System in early September.
The Arsenal Osteotomy Instrument Set is the latest extension to Arsenal, Alphatec’s new and innovative spinal fixation system. Developed to support complex spinal cases, the Arsenal Osteotomy Instrument Set was thoughtfully designed to provide procedural efficiency, ergonomic instrumentation and multiple instrument options to accommodate anatomical diversity. This comprehensive instrument set supports posterior column osteotomies, pedicle subtraction osteotomies and vertebral column resections. Many of these procedures are necessary when addressing complex spine cases, including deformity, which the Company estimates to be a $650M worldwide market. The Arsenal Osteotomy Instrument Set represents a milestone achievement supporting the Company’s Arsenal Deformity pipeline program.
“Alphatec continues to focus on innovation that further enhances the surgeon and patient surgical experiences,” said Jim Corbett, President and Chief Executive Officer of Alphatec Spine. “Continuing to expand the Arsenal platform to capture a broader surgeon market is a key component of our corporate strategy. Launching the new osteotomy set is a direct result of our execution of that strategy. We are excited about the prospects for Arsenal and the Arsenal Osteotomy Instrument Set as it provides a prelude into our deformity program in Q1 of 2016.”
About Alphatec Spine
Alphatec Spine, Inc., a wholly owned subsidiary of Alphatec Holdings, Inc., is a global medical device company that designs, develops, manufactures and markets spinal fusion technology products and solutions for the treatment of spinal disorders associated with disease and degeneration, congenital deformities and trauma. The Company's mission is to improve lives by delivering advancements in spinal fusion technologies. The Company and its affiliates market products in the U.S. and internationally via a direct sales force and independent distributors.
Additional information can be found at www.alphatecspine.com.
About the North American Spine Society (NASS)
The North American Spine Society is a global multidisciplinary medical society that utilizes education, research and advocacy to foster the highest quality, ethical, value-based and evidence-based spine care for patients. The society is comprised of almost 9000 members worldwide from disciplines including orthopedic surgery, neurosurgery, physical medicine and rehabilitation, pain management, physical/occupational therapy, anesthesiology, radiology and other health care professionals focused on the spine. Additional information can be found at www.nassannualmeeting.org.
Forward Looking Statements
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainty. Such statements are based on management's current expectations and are subject to a number of risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Alphatec Spine cautions investors that there can be no assurance that actual results or business conditions will not differ materially from those projected or suggested in such forward-looking statements as a result of various factors. Forward-looking statements include the Company's ability to achieve profitable growth; the Company’s ability to achieve both domestic and international growth and future profitability. The words "believe," "will," "should," "expect," "intend," "estimate" and "anticipate," variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. The important factors that could cause actual operating results to differ significantly from those expressed or implied by such forward-looking statements include, but are not limited to; the uncertainty of success in developing new products or products currently in Alphatec Spine's pipeline within forecast timeframes, or at all, including without limitation the products discussed in this press release; failure to achieve acceptance of Alphatec Spine's products by the surgeon community, including without limitation the products discussed in this press release; Alphatec Spine's ability to develop and expand its U.S. and/or global revenues; continuation of favorable third party payor reimbursement for procedures performed using Alphatec Spine's products, including the products discussed in this press release; unanticipated expenses or liabilities or other adverse events affecting cash flow or Alphatec Spine's ability to successfully control its costs or achieve profitability; uncertainty of additional funding; Alphatec Spine's ability to compete with other competing products and with emerging new technologies; product liability exposure; an unsuccessful outcome in any material litigation in which the Company is a defendant; patent infringement claims and claims related to Alphatec Spine's intellectual property. Please refer to the risks detailed from time to time in Alphatec Spine's SEC reports, including its Annual Report Form 10-K, as well as other filings on Form 10-Q and periodic filings on Form 8-K. Alphatec Spine disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, unless required by law.
CONTACT: Investor/Media Contact:Christine ZedelmayerAlphatec Spine, Inc.Investor Relations (760) firstname.lastname@example.org
Published at Nasdaq GlobeNewswire